secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001628280-24-014236
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen provides FY2023 update: FDA alignment for OCU400 Phase 3, RMAT designation, cash $39.5M, restatement planned
--------------------------------------------------------------------------------

- FDA alignment for broad retinitis pigmentosa indication in Phase 3 trial of OCU400; RMAT designation granted.
- Completed cohort 1 dosing for OCU410 (GA) and OCU410ST (Stargardt) in Phase 1/2 trials.
- Cash, cash equivalents, and investments $39.5M as of Dec 31, 2023, vs. $90.9M a year earlier; runway into Q4 2024.
- Intends to restate FY2022 and first three quarters of 2023 financials due to non-cash accounting error; no cash impact.
- OCU500 mucosal vaccine selected for NIAID Project NextGen; clinical trials expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024014236/0001628280-24-014236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828024014236/ocgn-20240402.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-014236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer